RNAi inhibition of alpha-ENaC expression
First Claim
Patent Images
1. A composition comprising an iRNA agent comprising a sense strand and an antisense strand, wherein:
- a. the sense strand comprises at least 15 contiguous nucleotides from the sense strand of ND8453 (SEQ ID NO;
1425), and the antisense strand comprises at least 15 contiguous nucleotides from the antisense strand of ND8453 (SEQ ID NO;
1426);
orb. the sense strand comprises at least 15 contiguous nucleotides from the sense strand of ND8489 (SEQ ID NO;
1497), and the antisense strand comprises at least 15 contiguous nucleotides from the antisense strand of ND8489 (SEQ ID NO;
1498);
orc. the sense strand comprises at least 15 contiguous nucleotides differing by 0, 1, 2 or 3 nucleotides from the sense strand of ND8456 (SEQ ID NO;
1431), and the antisense strand comprises at least 15 contiguous nucleotides differing by 0, 1, 2 or 3 nucleotides from the antisense strand of ND8456 (SEQ ID NO;
1432).
4 Assignments
0 Petitions
Accused Products
Abstract
The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
-
Citations
27 Claims
-
1. A composition comprising an iRNA agent comprising a sense strand and an antisense strand, wherein:
-
a. the sense strand comprises at least 15 contiguous nucleotides from the sense strand of ND8453 (SEQ ID NO;
1425), and the antisense strand comprises at least 15 contiguous nucleotides from the antisense strand of ND8453 (SEQ ID NO;
1426);
orb. the sense strand comprises at least 15 contiguous nucleotides from the sense strand of ND8489 (SEQ ID NO;
1497), and the antisense strand comprises at least 15 contiguous nucleotides from the antisense strand of ND8489 (SEQ ID NO;
1498);
orc. the sense strand comprises at least 15 contiguous nucleotides differing by 0, 1, 2 or 3 nucleotides from the sense strand of ND8456 (SEQ ID NO;
1431), and the antisense strand comprises at least 15 contiguous nucleotides differing by 0, 1, 2 or 3 nucleotides from the antisense strand of ND8456 (SEQ ID NO;
1432). - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)
-
-
17. A composition comprising an iRNA agent to alpha-ENaC, wherein the iRNA agent comprises a sense strand and an antisense strand, wherein the sense strand comprises at least 15 contiguous nucleotides differing by 0, 1, 2, or 3 nucleotides from the sense strand of an iRNA agent selected from the group consisting of ND8453 (SEQ ID NO:
- 1425), ND8489 (SEQ ID NO;
1497), and ND8456 (SEQ ID NO;
1431), and wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0, 1, 2, or 3 nucleotides from the antisense strand of an iRNA agent selected from the group consisting of ND8453 (SEQ ID NO;
1426);
ND8489 (SEQ ID NO;
1498), and ND8456 (SEQ ID NO;
1432), the composition further comprising an epithelial receptor ligand. - View Dependent Claims (18, 19, 20, 21)
- 1425), ND8489 (SEQ ID NO;
-
22. A method of treating a human subject having a pathological state mediated at least in part by alpha-ENaC expression, the method comprising the step of administering a therapeutically effective amount of a composition comprising an iRNA agent to alpha-ENaC, wherein the iRNA agent comprises a sense strand and an antisense strand, wherein the sense strand comprises at least 15 contiguous nucleotides differing by 0, 1, 2, or 3 nucleotides from the sense strand of an iRNA agent selected from the group consisting of ND8453 (SEQ ID NO:
- 1425), ND8489 (SEQ ID NO;
1497), and ND8456 (SEQ ID NO;
1431), and wherein the antisense strand comprises at least 15 contiguous nucleotides differing by 0, 1, 2, or 3 nucleotides from the antisense strand of an iRNA agent selected from the group consisting of ND8453 (SEQ ID NO;
1426);
ND8489 (SEQ ID NO;
1498), and ND8456 (SEQ ID NO;
1432). - View Dependent Claims (23, 24)
- 1425), ND8489 (SEQ ID NO;
-
25. A composition comprising an iRNA agent comprising a sense strand and an antisense strand, wherein the sense strand comprises at least 15 contiguous nucleotides from the sense strand of ND8453 (SEQ ID NO:
- 1425), and the antisense strand comprises at least 15 contiguous nucleotides from the antisense strand of ND8453 (SEQ ID NO;
1426).
- 1425), and the antisense strand comprises at least 15 contiguous nucleotides from the antisense strand of ND8453 (SEQ ID NO;
-
26. A composition comprising an iRNA agent comprising a sense strand and an antisense strand, wherein the sense strand comprises at least 15 contiguous nucleotides from the sense strand of ND8489 (SEQ ID NO:
- 1497), and the antisense strand comprises at least 15 contiguous nucleotides from the antisense strand of ND8489 (SEQ ID NO;
1498).
- 1497), and the antisense strand comprises at least 15 contiguous nucleotides from the antisense strand of ND8489 (SEQ ID NO;
-
27. A composition comprising an iRNA agent comprising a sense strand and an antisense strand, wherein the sense strand comprises at least 15 contiguous nucleotides differing by 0, 1, 2 or 3 nucleotides from the sense strand of ND8456 (SEQ ID NO:
- 1431), and the antisense strand comprises at least 15 contiguous nucleotides differing by 0, 1, 2 or 3 nucleotides from the antisense strand of ND8456 (SEQ ID NO;
1432).
- 1431), and the antisense strand comprises at least 15 contiguous nucleotides differing by 0, 1, 2 or 3 nucleotides from the antisense strand of ND8456 (SEQ ID NO;
Specification